Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT04984018 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of chidamide plus camrelizumab as second-line therapy for advanced esophageal squamous cell carcinoma treated with PD-1 blockade

NCT ID: NCT04976478 Not yet recruiting - Clinical trials for Cervical Squamous Cell Carcinoma

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Start date: July 2021
Phase:
Study type: Observational [Patient Registry]

To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma

NCT ID: NCT04937673 Not yet recruiting - Clinical trials for Thoracic Esophageal Squamous Cell Carcinoma

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, open, two arm phase II clinical study. 40 patients are included in the exploratory study. The dominant population with higher biomarker positive / IO score was identified to provide the basis for the later phase III study. The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. The treatment cycle was every 3 weeks. The curative effect was evaluated when the treatment cycle was 2, and the resection of esophageal cancer was considered after 3 cycles. Postoperative adjuvant therapy was based on the patient's condition and surgical results; For patients with R0 resection, postoperative adjuvant treatment is not recommended. For patients with R1 / R2 resection, multi-disciplinary joint discussion and consultation are recommended to propose individualized comprehensive treatment.

NCT ID: NCT04888403 Not yet recruiting - Clinical trials for Locally Advanced Esophageal Squamous Cell Carcinoma

Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma

Start date: December 31, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally and Advanced Esophageal Squamous Cell Carcinoma

NCT ID: NCT04882462 Not yet recruiting - Clinical trials for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Carpp-1
Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

This clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of Sintilimab and Nimotuzumab in combination with chemotherapy in patients with newly diagnosed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The main endpoint is progression free survival (PFS); the secondary endpoint are objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.

NCT ID: NCT04880811 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Start date: July 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.

NCT ID: NCT04866381 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Start date: April 2021
Phase: Phase 2
Study type: Interventional

This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.

NCT ID: NCT04861467 Not yet recruiting - HNSCC Clinical Trials

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.

NCT ID: NCT04843098 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start date: April 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.

NCT ID: NCT04814069 Not yet recruiting - Clinical trials for Head and Neck Cancer

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma:The POTENTIAL Study

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.